Clarus Builds Investment Team

Feb 10 2006 | 10:18pm ET

Clarus Ventures, a global life sciences venture capital firm with offices in San Francisco and Cambridge, Mass., has filled out its investment team to manage its first fund, which closed in December with $500 million in committed capital. The firm has hired three principals and a controller to help manage the fund and Robert Liptak, managing director, said the firm is looking to make one additional hire.

The newly-formed team includes Emmett Cunningham, Michele Park and Scott Requadt, who have joined the firm as principals, and Danielle Bechard, who has joined as controller.

Prior to joining the firm's San Francisco office, Cunningham was senior vice president of medical strategy at Eyetech Pharmaceuticals, where he played a leadership role in the development and approval of Macugen, a drug used to help age-related macular degeneration.

Park joins the San Francisco office of Clarus from Credit Suisse First Boston, where she was an analyst covering large, medium and small capitalization biotechnology companies with a focus on companies with oncologic and anti-infective products.

Requadt joins the Cambridge office from TransForm Pharmaceuticals, where he was director of business development.

Finally, Bechard joins the Cambridge office from the McDonald's Corporation, where she was responsible for franchisee analysis.

The fund will invest in predominantly later-stage biotechnology firms, Liptak said.


In Depth

Q&A: Schroders’ Forest Discusses Multi-Asset Investments On Eve Of U.S. Launch

Jul 17 2014 | 8:05am ET

Global investment manager Schroders has $446 billion in assets under management, $...

Lifestyle

Einhorns Busts At WSOP, Finishes In 173rd

Jul 15 2014 | 10:48am ET

Greenlight Capital founder David Einhorn’s World Series of Poker won’t end at...

Guest Contributor

Common Risk Parity Misperceptions

Jul 16 2014 | 11:02am ET

Over the past few years, risk parity has become a component of most investors’...

 

Sponsored Content

    Northern Trust Helps Hedge Funds Navigate Derivatives Regulations

    Jul 8 2014 | 10:48am ET

    The surge in derivatives regulation is among the most complex challenges facing the financial services industry today. Northern Trust’s Joshua Satten recently spoke with FINalternatives to share insights into the challenges presented by new regulation and explore how the industry is responding. Read more…

Publisher's Note